<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01760005</url>
  </required_header>
  <id_info>
    <org_study_id>DIAN-TU-001</org_study_id>
    <secondary_id>The Alzheimer's Association</secondary_id>
    <secondary_id>U01AG042791</secondary_id>
    <secondary_id>2013-000307-17</secondary_id>
    <secondary_id>R01AG046179</secondary_id>
    <secondary_id>REec-2014-0817</secondary_id>
    <secondary_id>The Alzheimer's Association</secondary_id>
    <secondary_id>The Alzheimer's Association</secondary_id>
    <secondary_id>R56AG053267</secondary_id>
    <secondary_id>GHR Foundation</secondary_id>
    <nct_id>NCT01760005</nct_id>
  </id_info>
  <brief_title>Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.</brief_title>
  <acronym>DIAN-TU</acronym>
  <official_title>A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alzheimer's Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Avid Radiopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Accelerating Medicines Partnership (AMP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, biomarker and cognitive
      efficacy of investigational products in subjects who are known to have an Alzheimer's
      disease-causing mutation by determining if treatment with the study drug slows the rate of
      progression of cognitive impairment and improves disease-related biomarkers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The mutations in presenilin 1 (PSEN1), presenilin 2 (PSEN2) and amyloid precursor protein
      (APP) that are associated with dominantly inherited Alzheimer's disease have very high
      penetrance (near 100%). This study will target individuals who are either known to have a
      disease-causing mutation or who are at risk for such a mutation (the child or sibling of a
      proband with a known mutation) and unaware of their genetic status. Because the age at onset
      of cognitive changes is relatively consistent within each family and with each mutation
      (Ryman, Acosta-Baena et al. 2014), an age at onset is determined for each affected parent or
      mutation. This study will enroll subjects who are either asymptomatic and are within a
      specific window of time of expected age at onset for their family and/or mutation or who have
      symptoms of mild Alzheimer's disease.

      The ability to identify individuals destined to develop Alzheimer's disease (AD) within the
      next 10-15 years with a high degree of confidence provides a unique opportunity to assess the
      efficacy of therapies while individuals are asymptomatic and/or very early stages of
      dementia. Families with known disease-causing mutations are extremely rare and are
      geographically dispersed throughout the world. These constraints necessitate a specialized
      study design. Many of the subjects in this study will not yet have any cognitive symptoms of
      AD; they will be &quot;asymptomatic&quot; carriers of mutations that cause dominantly inherited
      Alzheimer's disease and would be expected to perform normally on standard cognitive and
      functional testing. Imaging and fluid biomarkers will be used to demonstrate that the
      treatment compounds have engaged their therapeutic targets. A set of cognitive measures
      designed to assess the very earliest and most subtle cognitive changes will be collected.
      Additionally, because many at-risk individuals decide not to know whether they have the
      disease-associated mutation or not, some of the at-risk individuals enrolled in this study
      will not have the disease causing mutations; they will be &quot;mutation negative&quot;. It is
      important to enroll non-carrier subjects to avoid coercion (e.g., potential subjects may be
      pressured into genetic testing to learn their genetic status in order to be eligible for the
      trial). These mutation negative individuals will be assigned to the placebo group; and will
      not be included in the primary efficacy or futility analyses. Subjects and site study staff
      will remain blinded as to these individuals' active or placebo group assignment and mutation
      status. Thus, the study will be double blinded for placebo and for mutation status, except
      for mutation positive subjects who are aware of their genetic status. There may be
      exceptional circumstances when required by local regulation or health authorities where
      enrollment may be restricted to mutation carriers only but such mandates will be thoroughly
      documented and agreed upon by the governing regulatory agency and sponsor. Several different
      therapies (each referred to as a study drug arm) will be tested in order to increase the
      likelihood that an effective treatment will be discovered. The compounds are selected for
      this trial based on mechanism of action and available data on efficacy and safety profile.

      The study design includes a pooled placebo group shared by all study drug arms. Mutation
      positive subjects will be assigned to a study drug arm and subsequently randomized within
      that arm in an overall 3:1 ratio to active drug:placebo. Mutation negative subjects will all
      receive placebo treatment. Importantly, subjects and study staff will not be blinded as to
      which study drug arm (gantenerumab, solanezumab, JNJ-54861911) each subject has been
      assigned; they will be blinded as to whether subjects have been randomized to active drug or
      placebo. Biomarker data will be analyzed for pre-specified endpoints consistent with the
      drug's mechanism of action and known effects on the tested biomarkers. The primary cognitive
      endpoint will be the same for all study drug arms. This study is an adaptive platform based
      study. Interim analyses of the imaging or fluid biomarker endpoint will assess safety and
      whether each study drug engages its biological targets. This biomarker approach is
      particularly important in this study as most study subjects will be cognitively normal at
      baseline and most will remain cognitively normal during the first 2 years of the study. The
      cognitive composite is designed to assess subtle cognitive changes that may be detectable
      before the onset of dementia. The cognitive disease progression model (CDPM) endpoint design
      will allow for detection of these subtle cognitive changes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess cognitive efficacy in individuals with mutations causing dominantly inherited AD as measured by change in the DIAN-TU cognitive composite score.</measure>
    <time_frame>Baseline and Weeks 52, 104, 156, and 208</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gantenerumab: Cerebral amyloid imaging using [11C]PiB-PET.</measure>
    <time_frame>Baseline and Weeks 52, 104, and 208</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Total Abeta 1-42 (Aβ42) in CSF.</measure>
    <time_frame>Baseline, Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>JNJ-54861911: CSF amyloid-beta peptide concentration as measured by Abeta 1-42 (Aβ42) in CSF.</measure>
    <time_frame>Baseline, Week 208</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Clinical Measures</measure>
    <time_frame>Baseline, week 208</time_frame>
    <description>Clinical Dementia Rating (CDR), including CDR sum of boxes (CDR-SB) and clinician's diagnostic assessment
Geriatric Depression Scale (GDS)
Neuropsychiatric Inventory Questionnaire (NPI-Q)
Functional Assessment Questionnaire (FAQ)
Mini Mental Status Exam (MMSE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Cognitive Measures</measure>
    <time_frame>Baseline, week 208</time_frame>
    <description>International Shopping List Test (12-Item Word List Learning): 3 learning trials, Immediate Recall, 30-min Delayed Recall (CogState)
Groton Maze Learning Test: Timed Chase Task, 5 learning Trials, Immediate Recall, 30-min Delayed Recall (CogState)
Cogstate Detection Task
Cogstate Identification Test
Cogstate One Card Learning Test
Cogstate One-Back (OBK) Task
Behavioral Pattern Separation Object Task
Memory Complaint Questionnaire (MAC-Q)
Trails A &amp; B
Wechsler Memory Scale - Revised (WMS-R) Digit Span
Wechsler Adult Intelligence Scale - Revised (WAIS-R) Digit-Symbol Substitution Test
Raven's Progressive Matrices (Set A)
Category Fluency (Animals &amp; Vegetables)
Wechsler Memory Scale Logical Memory I Paragraph Memory (Immediate &amp; Delayed Recall)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety and Tolerability Outcome Measures</measure>
    <time_frame>Baseline, week 208</time_frame>
    <description>Neurological findings
Laboratory test results
ECG findings
Safety MRIs</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">438</enrollment>
  <condition>Alzheimers Disease</condition>
  <condition>Dementia</condition>
  <condition>Alzheimers Disease, Familial</condition>
  <arm_group>
    <arm_group_label>Gantenerumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Solanezumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo (Gantenerumab)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo (Solanezumab)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>JNJ-54861911</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo (JNJ-54861911)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gantenerumab</intervention_name>
    <description>Subcutaneously every 4 weeks at escalating doses</description>
    <arm_group_label>Gantenerumab</arm_group_label>
    <other_name>RO4909832</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solanezumab</intervention_name>
    <description>Intravenous infusion every 4 weeks at escalating doses</description>
    <arm_group_label>Solanezumab</arm_group_label>
    <other_name>LY2062430</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo (Gantenerumab)</intervention_name>
    <description>Subcutaneous injection of placebo every 4 weeks</description>
    <arm_group_label>Matching placebo (Gantenerumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo (Solanezumab)</intervention_name>
    <description>Intravenous infusion of placebo every 4 weeks</description>
    <arm_group_label>Matching Placebo (Solanezumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-54861911</intervention_name>
    <description>25 mg daily oral tablet</description>
    <arm_group_label>JNJ-54861911</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo (JNJ-54861911)</intervention_name>
    <description>Daily oral placebo tablet</description>
    <arm_group_label>Matching Placebo (JNJ-54861911)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 18-80 years of age

          -  Individuals who know they have an Alzheimer's disease-causing mutation or are unaware
             of their genetic status and have a 50% chance of having an autosomal dominant
             Alzheimer's disease (ADAD) mutation (e.g. parent or sibling with a known AD-causing
             mutation)

          -  Are within -15 to + 10 years of the predicted or actual age of cognitive symptom onset

          -  Cognitively normal or with mild cognitive impairment or mild dementia, Clinical
             Dementia Rating (CDR) of 0-1 (inclusive)

          -  Fluency in DIAN-TU trial approved language and evidence of adequate premorbid
             intellectual functioning

          -  Able to undergo Magnetic Resonance Imaging (MRI), Lumbar Puncture (LP), Positron
             Emission Tomography (PET), and complete all study related testing and evaluations.

          -  For women of childbearing potential, if partner is not sterilized, subject must agree
             to use effective contraceptive measures (hormonal contraception, intra-uterine device,
             sexual abstinence, barrier method with spermicide).

          -  Adequate visual and auditory abilities to perform all aspects of the cognitive and
             functional assessments.

          -  Has a Study Partner who in the investigator's judgment is able to provide accurate
             information as to the subject's cognitive and functional abilities, who agrees to
             provide information at the study visits which require informant input for scale
             completion.

        Exclusion Criteria:

          -  History or presence of brain MRI scans indicative of any other significant abnormality

          -  Alcohol or drug dependence currently or within the past 1 year

          -  Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or
             foreign metal objects in the eyes, skin or body which would preclude MRI scan.

          -  History or presence of clinically significant cardiovascular disease, hepatic/renal
             disorders, infectious disease or immune disorder, or metabolic/endocrine disorders

          -  Anticoagulants except low dose (≤ 325 mg) aspirin.

          -  Have been exposed to a monoclonal antibody targeting beta amyloid peptide within the
             past six months.

          -  History of cancer within the last 5 years, except basal cell carcinoma, non-squamous
             skin carcinoma, prostate cancer or carcinoma in situ with no significant progression
             over the past 2 years.

          -  Positive urine or serum pregnancy test or plans or desires to become pregnant during
             the course of the trial.

          -  Subjects unable to complete all study related testing, including implanted metal that
             cannot be removed for MRI scanning, required anticoagulation and pregnancy.

          -  JNJ-54861911 study arm only: Hypopigmentation abnormality of the skin such as
             vitiligo, other than small localized findings, at baseline dermatological test.

          -  JNJ-54861911 study arm only: Subjects with the APP Swedish Mutation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randall J Bateman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ellen Ziegemeier, MA</last_name>
    <phone>844-DIANEXR (342-6397)</phone>
    <email>dianexr@neuro.wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Petranek</last_name>
    <phone>844-DIANEXR (342-6397)</phone>
    <email>dianexr@neuro.wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama in Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Erik Roberson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Medical Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Doug Galasko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC Keck School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sonia Pawluczyk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christopher Van Dyck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>James Lah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jared Brosch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Barbara Snider</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lawrence Honig</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sarah Berman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Butler Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02096</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ghulam Surti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Health Hospital</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Diana Kerwin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Neurologicas Raul Carrea, FLENI</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aire</city>
        <zip>C1428AQK</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ricardo Allegri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuroscience Research Australia</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mental Health Research Institute</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The McCuster Foundation of Alzheimer's Disease Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina da USP</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ricardo Nitrini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UBC Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>McGill Center for Studies in Aging</name>
      <address>
        <city>Verdun</city>
        <state>Quebec</state>
        <zip>H4H 1R3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Serge Gauthier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec - Hôpital de l' Enfant Jésus</name>
      <address>
        <city>Québec</city>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Robert LaForce</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <state>Haute Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jérémie Pariente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Roger Salengro - CHU Lille</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Florence Pasquier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitie-Salpetriere</name>
      <address>
        <city>Paris cedex 13</city>
        <state>Paris</state>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bruno Dubois</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Neurologique Pierre Wertheimer</name>
      <address>
        <city>Bron cedex</city>
        <state>Rhone</state>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maité Formaglio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen - Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <state>Seine Maritime</state>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Didier Hannequin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tubingen</name>
      <address>
        <city>Tübingen</city>
        <state>Baden Wuerttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Cristoph Laske</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LMU-Campus Grosshadern</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Johannes Levin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>DUBLIN 4</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Justin Kinsella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Centro San Giovanni di Dio Fatebenefratelli</name>
      <address>
        <city>Brescia</city>
        <zip>25125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Giovanni Frisoni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sandro Sorbi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>14269</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ana Luisa Sosa Ortiz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.</name>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <zip>45030</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Miguel Angel Macias Islas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico, School of Medicine</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ivonne Jimenez-Velazquez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic I Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Raquel Sanchez Valle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The National Hospital for Neurology and Neurosurgery</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>WC1B 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Catherine Mummery</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.dianexr.org/</url>
    <description>Expanded registry</description>
  </link>
  <reference>
    <citation>Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC; Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012 Aug 30;367(9):795-804. doi: 10.1056/NEJMoa1202753. Epub 2012 Jul 11. Erratum in: N Engl J Med. 2012 Aug 23;367(8):780.</citation>
    <PMID>22784036</PMID>
  </reference>
  <reference>
    <citation>Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 2012 Jul;8(4):261-71. doi: 10.1016/j.jalz.2011.09.224. Epub 2012 Jun 5.</citation>
    <PMID>22672770</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2012</study_first_submitted>
  <study_first_submitted_qc>December 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2013</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Dementia</keyword>
  <keyword>Mutation</keyword>
  <keyword>Genetic Mutation</keyword>
  <keyword>Dominantly Inherited Alzheimer's Disease</keyword>
  <keyword>Dominantly Inherited Alzheimer's Network</keyword>
  <keyword>Autosomal Dominant Alzheimer's Disease</keyword>
  <keyword>Early Onset Alzheimer's Disease</keyword>
  <keyword>DIAN</keyword>
  <keyword>DIAN-TU</keyword>
  <keyword>DIAN TU</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

